Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Stopped The Sponsor made the decision to terminate the study and complete the final analysis for available data.

Conditions

• Colorectal Cancer Metastatic
• Myelosuppression-Adult
• Chemotherapeutic Toxicity

Interventions

• DRUG: Trilaciclib
• DRUG: Placebo

Sponsor

G1 Therapeutics, Inc.